NorthRock Partners LLC Acquires New Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

NorthRock Partners LLC bought a new stake in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 933 shares of the biotechnology company's stock, valued at approximately $555,000.

A number of other large investors have also modified their holdings of the company. Asset Dedication LLC raised its holdings in Axon Enterprise by 11.3% in the 4th quarter. Asset Dedication LLC now owns 178 shares of the biotechnology company's stock valued at $106,000 after acquiring an additional 18 shares in the last quarter. Bleakley Financial Group LLC raised its holdings in Axon Enterprise by 1.3% in the 4th quarter. Bleakley Financial Group LLC now owns 1,527 shares of the biotechnology company's stock valued at $908,000 after acquiring an additional 20 shares in the last quarter. Venturi Wealth Management LLC raised its holdings in Axon Enterprise by 2.7% in the 4th quarter. Venturi Wealth Management LLC now owns 802 shares of the biotechnology company's stock valued at $477,000 after acquiring an additional 21 shares in the last quarter. Beacon Pointe Advisors LLC raised its holdings in Axon Enterprise by 2.6% in the 4th quarter. Beacon Pointe Advisors LLC now owns 864 shares of the biotechnology company's stock valued at $513,000 after acquiring an additional 22 shares in the last quarter. Finally, Burns Matteson Capital Management LLC raised its holdings in Axon Enterprise by 3.4% in the 4th quarter. Burns Matteson Capital Management LLC now owns 757 shares of the biotechnology company's stock valued at $450,000 after acquiring an additional 25 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Stock Up 0.1%

Shares of AXON traded up $0.43 during mid-day trading on Tuesday, reaching $742.75. The company had a trading volume of 383,468 shares, compared to its average volume of 751,632. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The firm has a 50-day moving average price of $588.30 and a 200 day moving average price of $597.92. Axon Enterprise, Inc. has a 52 week low of $273.52 and a 52 week high of $744.51. The company has a market capitalization of $57.82 billion, a price-to-earnings ratio of 191.93, a price-to-earnings-growth ratio of 5.17 and a beta of 1.24.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The company had revenue of $603.63 million during the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The firm's revenue for the quarter was up 31.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.15 EPS. On average, sell-side analysts forecast that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Insider Transactions at Axon Enterprise

In related news, Director Jeri Williams sold 307 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $552.72, for a total value of $169,685.04. Following the completion of the transaction, the director now owns 1,627 shares of the company's stock, valued at approximately $899,275.44. This trade represents a 15.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the completion of the sale, the chief executive officer now directly owns 3,063,982 shares in the company, valued at $1,657,583,622.18. This trade represents a 0.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 25,064 shares of company stock worth $15,817,127 in the last three months. Corporate insiders own 4.40% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on AXON. JMP Securities reiterated an "outperform" rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. The Goldman Sachs Group lifted their price target on Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th. Northcoast Research lowered Axon Enterprise from a "buy" rating to a "neutral" rating in a research note on Wednesday, February 19th. Needham & Company LLC lifted their price target on Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Finally, Barclays boosted their price objective on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $652.73.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.